8-K: Outlook Therapeutics Seeks FDA Meeting After ONS-5010 CRL

Outlook Therapeutics has requested a Type A meeting with the FDA to discuss the Complete Response Letter for its ONS-5010 BLA for wet AMD, citing disagreement with the FDA's determination.

Summary

• Outlook Therapeutics submitted a Type A meeting request to the U.S. Food and Drug Administration (FDA) on February 11, 2026.
• The meeting is to discuss the Complete Response Letter (CRL) received from the FDA, dated December 30, 2025 (as per Exhibit 99.1) or December 31, 2025 (as per Form 8-K), regarding the Biologics License Application (BLA) for ONS-5010/LYTENAVA (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD).
• The CRL identified a single deficiency based on a purported lack of substantial evidence of effectiveness and recommended submission of additional confirmatory evidence.
• Outlook Therapeutics believes this determination is inconsistent with the totality of evidence submitted, including data from the NORSE TWO and NORSE EIGHT Phase 3 trials, and other confirmatory evidence.
• The company found the issuance of an additional CRL unexpected, especially after prior discussions with the FDA in September 2025 where they understood alignment on BLA resubmission requirements had been achieved.
• ONS-5010 has demonstrated a favorable safety profile, with ocular adverse reactions consistent with the control arm (ranibizumab) and intravitreal injections generally, and the FDA has not expressed any safety concerns.
• LYTENAVA (bevacizumab gamma) received Marketing Authorization from the European Commission and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for wet AMD.
• Commercial launch of LYTENAVA commenced in Germany and the UK in June 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significant setback for Outlook Therapeutics' US market entry for ONS-5010, despite European approvals. The unexpected CRL and the need for further confirmatory evidence introduce substantial uncertainty and delay, negatively impacting investor confidence.

Positives

• ONS-5010 demonstrated a favorable safety profile, consistent with the control arm (ranibizumab) and intravitreal injections generally, with no FDA safety concerns expressed.
• LYTENAVA (bevacizumab gamma) received Marketing Authorization from the European Commission in the EU and the MHRA in the UK for the treatment of wet AMD.
• Commercial launch of LYTENAVA commenced in Germany and the UK in June 2025, establishing a presence in key European markets.
• The company remains confident in the strength of its clinical evidence supporting ONS-5010 and is committed to working constructively with the FDA.
• ONS-5010 is supported by a fully domestic, end-to-end U.S. manufacturing supply chain, enhancing reliability of supply.

Negatives

• Received a Complete Response Letter (CRL) from the FDA dated December 30, 2025 (or December 31, 2025) for the ONS-5010 BLA for wet AMD.
• The CRL cited a purported lack of substantial evidence of effectiveness and recommended submission of additional confirmatory evidence, indicating a significant regulatory hurdle.
• The issuance of an additional CRL was unexpected by Outlook Therapeutics, especially after prior discussions in September 2025 where they believed alignment with the FDA on resubmission requirements had been achieved.
• NORSE EIGHT, a second adequate and well-controlled Phase 3 study, did not meet its primary endpoint at 8 weeks, although it showed a positive trajectory through 12 weeks.

Risks

• Risks associated with developing and commercializing pharmaceutical product candidates.
• Risks of conducting clinical trials and obtaining necessary regulatory approvals.
• The risk that Outlook Therapeutics may not be able to provide sufficient evidence to support the approval by the FDA of the ONS-5010 BLA.
• Uncertainty regarding the content and timing of decisions by regulatory bodies.
• The sufficiency of Outlook Therapeutics' resources to address ongoing regulatory requirements and commercialization efforts.
• Uncertainty of market conditions and future impacts related to macroeconomic factors, including ongoing overseas conflicts, tariffs and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment.

Future Outlook

Outlook Therapeutics plans to conduct a Type A meeting with the FDA to discuss and resolve the deficiency identified in the Complete Response Letter for ONS-5010. The company intends to continue working with the FDA to find a path forward for addressing the request for additional confirmatory evidence. Beyond the US, Outlook Therapeutics plans to expand its commercial presence in select European countries and is exploring collaborations with potential commercial and distribution partners in additional European countries and outside of Europe.

Management Comments

• "Outlook Therapeutics remains confident in the strength of the clinical evidence supporting ONS-5010 and firmly believes the totality of data meets the FDAs substantial evidence standard." Bob Jahr, Chief Executive Officer.
• "We are committed to working constructively with the FDA to resolve these issues and to bringing this important therapy to patients with wet AMD in the United States." Bob Jahr, Chief Executive Officer.

Industry Context

StockSavvy.ai notes that the market for wet AMD treatments is highly competitive, dominated by established anti-VEGF therapies. The potential approval of ONS-5010 as the first FDA-approved ophthalmic formulation of bevacizumab could offer a standardized, high-quality option, potentially mitigating risks associated with the current off-label use of repackaged bevacizumab. While European and UK marketing authorizations provide a significant foothold, US approval remains critical for broader market penetration and competitive positioning against existing treatments.

Comparison to Industry Standards

• NORSE TWO, a single adequate and well-controlled Phase 3 trial, demonstrated statistically significant and clinically relevant improvements in visual acuity at 12 months, meeting its primary endpoint (patients gaining three lines/15 letters of visual acuity) and a key secondary endpoint of mean change from baseline in visual acuity.
• ONS-5010's safety profile was consistent with the control arm, ranibizumab, and with intravitreal injections generally.
• LYTENAVA (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the European Union and UK, setting a new standard in those regions.

Stakeholder Impact

• Shareholders: Potential negative impact due to delayed US market entry, increased regulatory uncertainty, and potential need for further investment, which could affect stock price.
• Patients with wet AMD (US): Delayed access to a potentially new FDA-approved ophthalmic bevacizumab option, which could offer a standardized treatment.
• Employees: Potential impact on morale and strategic focus due to ongoing regulatory hurdles and extended timelines.
• Investment Professionals: Requires re-evaluation of OTLK's valuation, risk profile, and timeline for US market penetration.

Next Steps

• Conduct a Type A meeting with the FDA to discuss the Complete Response Letter and the identified deficiency.
• Work constructively with the FDA to resolve the issues and address the request for additional confirmatory evidence.
• Continue to expand commercial presence for LYTENAVA in select countries in Europe.
• Speak with and explore collaborations with potential commercial and distribution partners in additional European countries and outside of Europe.

Key Dates

Recommendation

The unexpected Complete Response Letter from the FDA, citing a lack of substantial evidence of effectiveness for ONS-5010, represents a significant regulatory setback and introduces considerable uncertainty regarding the drug's approval in the crucial U.S. market. While European approvals are a positive, the U.S. market is paramount. The need for further confirmatory evidence and the ensuing delays will likely impact the company's financial projections and increase operational risks. This development warrants a cautious stance, suggesting a 'sell' recommendation until a clear path to FDA approval is established and the associated timelines and costs are better understood.

Keywords

Outlook Therapeutics, OTLK, ONS-5010, LYTENAVA, bevacizumab-vikg, wet AMD, FDA, Complete Response Letter, BLA, Type A Meeting, ophthalmic, retina diseases, biopharmaceutical, NORSE TWO, NORSE EIGHT, drug approval, regulatory